ValuEngine cut shares of Celsion (NASDAQ:CLSN) from a sell rating to a strong sell rating in a research note released on Thursday, March 15th.
Several other research firms have also recently issued reports on CLSN. Zacks Investment Research cut Celsion from a buy rating to a hold rating in a research report on Thursday, January 11th. Oppenheimer began coverage on Celsion in a research report on Tuesday, November 21st. They issued an outperform rating and a $9.00 price objective for the company. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Celsion presently has a consensus rating of Hold and an average target price of $11.90.
NASDAQ:CLSN traded down $0.03 during trading hours on Thursday, hitting $2.20. The company’s stock had a trading volume of 78,321 shares, compared to its average volume of 205,689. The stock has a market capitalization of $39.03, a price-to-earnings ratio of -0.92 and a beta of 1.66. Celsion has a 52-week low of $1.24 and a 52-week high of $6.06.
An institutional investor recently bought a new position in Celsion stock. Virtu Financial LLC bought a new stake in Celsion Co. (NASDAQ:CLSN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned about 0.24% of Celsion as of its most recent filing with the Securities & Exchange Commission. 3.84% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Celsion (NASDAQ:CLSN) Cut to Strong Sell at ValuEngine” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/08/celsion-clsn-stock-rating-lowered-by-valuengine.html.
Celsion Company Profile
Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.